Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Leases (2019 - 2022)

Historic Leases for Iterum Therapeutics (ITRM) over the last 4 years, with Q3 2022 value amounting to $1.9 million.

  • Iterum Therapeutics' Leases fell 5233.69% to $1.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.9 million, marking a year-over-year decrease of 5233.69%. This contributed to the annual value of $3.7 million for FY2021, which is 2889.18% down from last year.
  • Per Iterum Therapeutics' latest filing, its Leases stood at $1.9 million for Q3 2022, which was down 5233.69% from $2.2 million recorded in Q2 2022.
  • Iterum Therapeutics' Leases' 5-year high stood at $7.5 million during Q1 2019, with a 5-year trough of $1.9 million in Q3 2022.
  • For the 4-year period, Iterum Therapeutics' Leases averaged around $5.3 million, with its median value being $5.3 million (2020).
  • In the last 5 years, Iterum Therapeutics' Leases tumbled by 646.32% in 2020 and then crashed by 5233.69% in 2022.
  • Iterum Therapeutics' Leases (Quarter) stood at $7.1 million in 2019, then decreased by 26.36% to $5.3 million in 2020, then dropped by 28.89% to $3.7 million in 2021, then tumbled by 50.39% to $1.9 million in 2022.
  • Its last three reported values are $1.9 million in Q3 2022, $2.2 million for Q2 2022, and $3.7 million during Q1 2022.